23 May 2024 : Database Analysis
MRTO4 Enhances Glycolysis to Facilitate HCC Progression by Inhibiting ALDOB
Yongyuan Zheng1ABCD, Yansong Huang1CDE, Weibing Li1CD, Hongqiu Cheng1AEG*DOI: 10.12659/MSM.944685
Med Sci Monit 2024; 30:e944685
Table 4 Univariate and multivariate Cox regression analyses of clinical characteristics associated with overall survival.
| Characteristics | Total (N) | OR (95% CI) | P value |
|---|---|---|---|
| Pathologic T stage (T2 & T3 & T4 vs T1) | 371 | 2.485 (1.637–3.773) | * |
| Pathologic N stage (N1 vs N0) | 258 | 0.969 (0.134–6.986) | 0.975 |
| Pathologic M stage (M1 vs M0) | 272 | 0.300 (0.031–2.923) | 0.300 |
| Pathologic stage (Stage III & Stage IV vs Stage I & Stage II) | 350 | 1.571 (0.967–2.552) | 0.068 |
| Tumor status (with tumor vs tumor free) | 355 | 1.556 (1.019–2.374) | 0.040* |
| Gender (Male vs Female) | 374 | 1.076 (0.698–1.660) | 0.740 |
| Age (>60 vs ≤60) | 373 | 0.889 (0.592–1.335) | 0.570 |
| Race (Black or African American & White vs Asian) | 362 | 0.591 (0.389–0.898) | * |
| Histological type (fibrolamellar carcinoma & hepatocholangiocarcinoma (mixed) vs hepatocellular carcinoma) | 374 | 1.000 (0.285–3.513) | 1.000 |
| BMI (>25 vs ≤25) | 337 | 0.568 (0.368–0.874) | * |
| Residual tumor (R1 & R2 vs R0) | 345 | 1.305 (0.502–3.389) | 0.585 |
| Histologic grade (G3 & G4 vs G1 & G2) | 369 | 2.702 (1.742–4.193) | * |
| AFP(ng/ml) (>400 vs ≤400) | 280 | 2.044 (1.161–3.597) | * |
| Albumin(g/dl) (≥3.5 vs <3.5) | 300 | 1.022 (0.595–1.754) | 0.938 |
| Prothrombin time (>4 vs ≤4) | 297 | 0.674 (0.407–1.116) | 0.125 |
| Child-Pugh grade (B & C vs A) | 241 | 1.212 (0.504–2.914) | 0.667 |
| Vascular invasion (Yes vs No) | 318 | 1.860 (1.165–2.970) | * |
| Adjacent hepatic tissue inflammation (Mild & Severe vs None) | 237 | 1.436 (0.858–2.403) | 0.168 |
| Weight (>70 vs ≤70) | 346 | 0.427 (0.277–0.657) | * |
| Height (≥170 vs <170) | 341 | 0.748 (0.485–1.153) | 0.189 |
| Bold values indicate * P HR – hazard ratio; CI – confidence interval. | |||